Technical Analysis for CTSO - Cytosorbents Corporation

Grade Last Price % Change Price Change
grade B 13.05 1.16% 0.15
CTSO closed up 1.16 percent on Tuesday, September 18, 2018, on 73 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Down
See historical CTSO trend table...

Date Alert Name Type % Chg
Sep 18 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Sep 18 Stochastic Reached Oversold Weakness 0.00%
Sep 18 Oversold Stochastic Weakness 0.00%
Sep 17 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 1.16%
Sep 17 Wide Bands Range Expansion 1.16%
Sep 14 20 DMA Resistance Bearish 1.56%
Sep 14 New Downtrend Bearish 1.56%
Sep 14 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 1.56%
Sep 14 Wide Bands Range Expansion 1.56%
Sep 14 Down 3 Days in a Row Weakness 1.56%

Older signals for CTSO ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
CytoSorbents Corporation, a development stage company, is engaged in the research, development, and commercialization of medical devices with its platform blood purification technology incorporating a proprietary adsorbent polymer technology. The company develops its adsorbent polymer technology for various applications in the medical field, primarily to provide blood purification for acute and chronic health complications associated with blood toxicity. Its principal product is CytoSorb device, an extracorporeal cytokine filter designed for the adjunctive therapy in the treatment of sepsis; for the adjunctive therapy in other critical care applications, including acute respiratory distress syndrome, severe burn injury, trauma, and pancreatitis; to prevent and treat organ dysfunction in brain-dead organ donors to increase the number and quality of viable organs harvested from donors; and for the prevention and treatment of post-operative complications of cardiopulmonary bypass surgery. The company is also developing HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it is developing BetaSorb device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; and DrugSorb, an extracorporeal hemoperfusion cartridge designed to remove toxic chemicals from the blood. The company was formerly known as MedaSorb Technologies Corporation and changed its name to CytoSorbents Corporation in May 2010. CytoSorbents Corporation was founded in 1997 and is based in Monmouth Junction, New Jersey.
Is CTSO a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 14.95
52 Week Low 5.35
Average Volume 237,325
200-Day Moving Average 9.4022
50-Day Moving Average 12.499
20-Day Moving Average 13.4838
10-Day Moving Average 13.6675
Average True Range 0.5904
ADX 23.62
+DI 19.3516
-DI 20.5375
Chandelier Exit (Long, 3 ATRs ) 13.1788
Chandelier Exit (Short, 3 ATRs ) 12.9212
Upper Bollinger Band 15.4168
Lower Bollinger Band 11.5508
Percent B (%b) 0.39
BandWidth 28.671443
MACD Line 0.2745
MACD Signal Line 0.4704
MACD Histogram -0.1959
Fundamentals Value
Market Cap 367.13 Million
Num Shares 28.1 Million
EPS -0.37
Price-to-Earnings (P/E) Ratio -35.27
Price-to-Sales 13.98
Price-to-Book 21.53
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 13.58
Resistance 3 (R3) 13.57 13.38 13.49
Resistance 2 (R2) 13.38 13.25 13.39 13.46
Resistance 1 (R1) 13.22 13.17 13.30 13.23 13.43
Pivot Point 13.03 13.03 13.08 13.04 13.03
Support 1 (S1) 12.87 12.90 12.95 12.88 12.67
Support 2 (S2) 12.68 12.82 12.69 12.64
Support 3 (S3) 12.52 12.68 12.61
Support 4 (S4) 12.53